Medications and CGM Coverage Guide: 2023 Q1 Edition

Last updated 03/14/2023
Quickly reference insurance plan coverage in this all-in-one guide for your patients with type 2 diabetes.
Medications and devices referenced include:
SGLT-2 Inhibitors
Jardiance, Farxiga, Invokana, Steglatro
GLP1-Receptor Agonists / GIPs
Trulicity, Ozempic, Victoza, Rybelsus, Bydureon BCise, Mounjaro
Anti-Obesity Medications
Saxenda, Wegovy, phentermine, Lomaira, Qsymia, Contrave
Continuous glucose monitors (CGMs)
Device brands preferred by each payor
Plans include major commercial plans/PBMs in Michigan (Aetna, BCBSM, Express Scripts, HAP, Priority Traditional, Priority Optimized, and United), as well as Medicare, Medicare Advantage plans (Aetna, BCBSM/BCN, HAP, Humana, Priority, United, and Wellcare), and Michigan Medicaid.
Developed by the Michigan Collaborative for Type 2 Diabetes.


For ProvidersNon-videoPDFMedicareCreated-By-MCT2DPoint-of-careCoverage

Subscribe to the MCT2D Newsletter

* indicates required
Blue Cross Blue Shield Blue Care Network of Michigan

Support for the Michigan Collaborative on Type 2 Diabetes is provided by Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. BCBSM’s Value Partnerships program provides clinical and executive support for all CQI programs. To learn more about Value Partnerships, visit Although Blue Cross Blue Shield of Michigan and the Michigan Collaborative on Type 2 Diabetes work in partnership, the opinions, beliefs, and viewpoints expressed by MCT2D do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.